exome sequencing
GeneDx Stock Plummets Despite 42 Percent Q1 Revenue Growth
The company reported a 42 percent year-over-year increase in first quarter revenues, driven by continuing strong demand for whole-genome and whole-exome testing.
The clinical genetic testing company's Q4 revenues jumped 64 percent year over year to $95.6 million, driven by its strong exome and whole-genome testing business.
GeneDx Shares Fall on Short Seller Report
Several Wall Street analysts took issue with the short seller's report, calling the claims false and unrelated to GeneDx's current operations.
Through close collaboration of more than 300 genomics and disease experts, the pan-European consortium solved more than 500 difficult cases.
GeneDx Launches Program to Boost Access to Exome Testing for Pediatric Epilepsy Patients
In partnership with Biogen, Praxis Precision Medicines, and Stoke Therapeutics, the program will also contribute to GeneDx's rare disease database.